Lilly misses analyst estimates, lowers profit forecast

Back to TopCommentsE-mailPrintBookmark and Share

Third-quarter profit at Eli Lilly and Co. missed analysts' estimates, and the Indianapolis-based drugmaker lowered its profit forecast by 4 cents per share for the remainder of the year.

Shares in Lilly were down more than 2 percent at midday Wednesday, to $50.76 each.

Lilly earned $1.3 billion during the three months ended Sept. 30, up by 7 percent from the same period a year ago. But that boost was due largely to an early payoff from former drug-development partner Amylin Pharmaceuticals Inc.

Excluding the Amylin payments and other special items, Lilly’s profit would have fallen to $888 million, a whopping 29-percent decline from the same period last year. On that basis, earnings per share were 79 cents in the most recent quarter.

Wall Street analysts were expecting 83 cents per share, according to a survey by Thomson Reuters.

Lilly’s revenue also was below analysts’ forecasts. The company brought in $5.44 billion during the quarter, down 11 percent from the same quarter last year. Analysts were expecting $5.62 billion.

Lilly lowered its full-year profit forecast to a range of $3.68 per share to $3.78 per share. Larger asset impairment and restructuring costs shaved 4 cents from the forecast issued in August.

However, excluding all special gains or losses, Lilly still expects to earn from $3.30 per share to $3.40 per share, the same as it had forecast in August.

“Lilly reported a ho-hum quarter,” Mark Schoenebaum, an analyst with ISI Group in New York, said in a note to clients, according to Bloomberg News. “Marginally weak financial quarter, but nothing terrible.”

Lilly’s revenue has been falling because its former bestseller Zyprexa lost patent protection a year ago. Lilly has been trying to offset the loss of $2.5 billion in Zyprexa revenue so far this year by improving sales of other drugs.

In the third quarter, sales of the antidepressant Cymbalta, the osteoporosis drug Forteo and Lilly’s animal health products all grew 20 percent or more over the same quarter last year.

Lilly also received $1.26 billion from Amylin following Amylin's acquisition by New York-based Bristol-Myers Squibb Co. Lilly and Amylin had co-developed the diabetes drugs Byetta and Bydureon. But a dispute last year led to a break-up of their partnership.

Lilly’s shares fell Tuesday prior to the earnings announcement by less than 1 percentage point, to $51.91. The stock had been flat all year until Aug. 24, when Lilly announced its experimental Alzheiemer’s drug solanezumab had shown some positive effects on patients. Since then, Lilly’s shares have traded up 22 percent.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. John, unfortunately CTRWD wants to put the tank(s) right next to a nature preserve and at the southern entrance to Carmel off of Keystone. Not exactly the kind of message you want to send to residents and visitors (come see our tanks as you enter our city and we build stuff in nature preserves...

  2. 85 feet for an ambitious project? I could shoot ej*culate farther than that.

  3. I tried, can't take it anymore. Untill Katz is replaced I can't listen anymore.

  4. Perhaps, but they've had a very active program to reduce rainwater/sump pump inflows for a number of years. But you are correct that controlling these peak flows will require spending more money - surge tanks, lines or removing storm water inflow at the source.

  5. All sewage goes to the Carmel treatment plant on the White River at 96th St. Rainfall should not affect sewage flows, but somehow it does - and the increased rate is more than the plant can handle a few times each year. One big source is typically homeowners who have their sump pumps connect into the sanitary sewer line rather than to the storm sewer line or yard. So we (Carmel and Clay Twp) need someway to hold the excess flow for a few days until the plant can process this material. Carmel wants the surge tank located at the treatment plant but than means an expensive underground line has to be installed through residential areas while CTRWD wants the surge tank located further 'upstream' from the treatment plant which costs less. Either solution works from an environmental control perspective. The less expensive solution means some people would likely have an unsightly tank near them. Carmel wants the more expensive solution - surprise!